Pfizer said it will offer a third dose to 144 volunteers, drawing from people who participated in the vaccine’s early-stage U.S. testing last year. Pfizer announced on Thursday that it has begun studying a third dose of its COVID-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus. Health authorities say first-generation COVID-19 vaccines still protect against variants that are emerging in different parts of the world. Pfizer said it will offer a third dose to 144 volunteers, drawing from people who participated in the vaccine’s early-stage U.S. testing last year. Pfizer and its German partner, BioNTech, also are tweaking their vaccine recipe.

Source: The Hindu February 25, 2021 12:47 UTC